Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate at the JCA-AACR Precision Cancer Medicine International Conference
13 sept. 2021 08h00 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results
16 août 2021 16h05 HE | Kinnate Biopharma
Announced first patient dosed in Phase 1 trial evaluating KIN-2787 in patients with BRAF mutation-positive solid tumors Strengthened management team and Board of Directors with key appointments ...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate in the 2021 Wedbush PacGrow Healthcare Conference
27 juil. 2021 08h00 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021
07 juil. 2021 16h05 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors
28 juin 2021 08h00 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expands its Leadership Team with Key New Hires
07 juin 2021 08h00 HE | Kinnate Biopharma
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team SAN FRANCISCO and SAN DIEGO, June 07, 2021 ...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021
04 juin 2021 08h00 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference
25 mai 2021 16h05 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Reports First Quarter 2021 Financial Results and Announces FDA Clearance of Investigational New Drug Application for KIN-2787
17 mai 2021 16h05 HE | Kinnate Biopharma
KIN-2787 is the company’s RAF inhibitor candidate for patients with mutant BRAF-driven solid tumors Planned initiation of Phase 1 clinical trial for KIN-2787 in mid-2021 Ended the quarter with cash...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture
13 mai 2021 16h02 HE | Kinnate Biopharma
Financing led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite CapitalThe joint venture will have exclusive license to develop and commercialize Kinnate’s...